AUTL Autolus Therapeutics ADS

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2024 financial results and operational highlights before open of US markets on Thursday, March 20, 2025.

Management will host a conference call and webcast at 8:30 am EDT/12:30 pm GMT to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the of Autolus’ website. 

About Autolus Therapeutics plc

Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit

Contact:  

Amanda Cray 

 

 

Olivia Manser 

8 

 



EN
06/03/2025

Underlying

AUTLAutolus Therapeutics ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Autolus Therapeutics ADS

Jacob Mekhael
  • Jacob Mekhael
AUTL Autolus Therape...

Autolus FIRST LOOK: FY24 results hold no surprises, upcoming R&D day

Yesterday before US market opens, Autolus reported unsurprising FY24 results with a cash position of $ 588m (YE23: $ 239.6m), sufficient to drive Aucatzyl's (obe-cel, CD19 CAR-T) launch in r/r adult ALL, and advance the company's pipeline towards pivotal autoimmune data. While the company did not share sales figures/patients dosed with Aucatzyl in the US (1Q25 sales figures to be communicated during the quarterly update), management confirmed that the launch is tracking well compared to their ex...

AUTL AUTOLUS THERAPEUTICS ADS
03/21/25 March 21, 2025 1 EN
Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Sharad Kumar S.P
  • Thomas Couvreur
  • Wim Lewi
EXM EXMAR N.V.
BREB BREDERODE S.A.
AUTL AUTOLUS THERAPEUTICS ADS
HYL HYLORIS PHARMACEUTICALS
03/21/25 March 21, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financi...

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates AUCATZYL® (obecabtagene autoleucel) U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and EMA marketing authorizations expected in H2 2025Initial six patients dosed in Phase 1 dose confirmation trial in Systemic Lupus Erythematosus (SLE) Company to provide clinical development program updates, including plans for expansion in autoimmune diseases, at R&D investor event to be held on...

March 20, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results a...

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025 LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2024 financial results and operational highlights before open of US markets on Thursday, March 20, 2025. Management will host a conference call and webcast at 8:30 am EDT/12:30 pm GMT to dis...

March 6, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics to Participate in Upcoming Investor Conferences LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in two upcoming investor conferences. Jefferies Biotech on the Beach SummitManagement to host investor meetingsDate: March 11, 2025Location: Miami, FL Leerink Global Biopharma ConferenceFireside Chat PresentationDate and time: March 12, 2025; 8:40am EDT / 12:40pm G...

March 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch